<DOC>
	<DOCNO>NCT01352026</DOCNO>
	<brief_summary>Treatment PAH include exercise limitation , non specific agent ( anticoagulant , diuretic supplemental oxygen ) , pulmonary specific vasodilator antiproliferative agent . Recent data obtain group , within rat PAH model , show antihyperglycemic drug metformin , use France since 1959 diabetic type II patient , significantly act pulmonary artery level . According result , know metformin widely use drug , favorable safety profile , investigator decide set pilot study , order evaluate activity metformin PAH treatment . In parallel , investigator focus metformin mechanism action .</brief_summary>
	<brief_title>Evaluation Metformin Activity Addition Conventional Treatment Grade II III Pulmonary Arterial Hypertension ( PAH )</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Familial Primary Pulmonary Hypertension</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<criteria>Men woman age 18 80 Patients include precapillary PAH stable 3 month Patient 6minute walk test comparable last 3 month inclusion Informed consent sign</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>August 2012</verification_date>
</DOC>